Spectroscopic analysis of the interaction of Lomustine (cas 13010-47-4) with calf thymus DNA
-
Add time:08/31/2019 Source:sciencedirect.com
Investigation of drug–DNA interaction is important for understanding the drug action at molecular level and for designing specific DNA targeted drug. Lomustine (cas 13010-47-4) (CCNU = 1-[2-chloroethyl]-3-cyclohexyl-1-nitroso-urea) is an alkylating antineoplastic nitrosourea derivative, used to treat different types of cancer. In the present study, conformational and structural effects of lomustine on DNA are investigated using different spectroscopic approaches. Different drug/DNA molar ratios are analyzed to determine the binding sites and binding mode of lomustine with DNA. Fourier transform infrared spectroscopic (FTIR) results suggest binding of lomustine with nitrogenous bases guanine and cytosine along with weak interaction to the sugar-phosphate backbone of DNA. Circular dichroism (CD) spectroscopic results show perturbation in the local conformation of DNA upon binding of lomustine with DNA helix. These local conformational changes may act as recognition site for alkylating enzymes that further causes alkylation of DNA. Spectroscopic results confirm the formation of an intermediate stage of DNA that occurs during the transition of B-conformation into A-conformation.
We also recommend Trading Suppliers and Manufacturers of Lomustine (cas 13010-47-4). Pls Click Website Link as below: cas 13010-47-4 suppliers
Prev:ArticlesRegorafenib compared with Lomustine (cas 13010-47-4) in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
Next:Original ArticleCombination toceranib and Lomustine (cas 13010-47-4) shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- ArticlesSingle-agent bevacizumab or Lomustine (cas 13010-47-4) versus a combination of bevacizumab plus Lomustine (cas 13010-47-4) in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial09/04/2019
- Short communicationA stability-indicating liquid chromatographic method for Lomustine (cas 13010-47-4)09/03/2019
- ArticlesLomustine (cas 13010-47-4)-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial09/02/2019
- Original ArticleCombination toceranib and Lomustine (cas 13010-47-4) shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study09/01/2019
- ArticlesRegorafenib compared with Lomustine (cas 13010-47-4) in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial08/30/2019
- Lomustine (cas 13010-47-4)08/29/2019
- Electrochemical behaviour of anticancer drug Lomustine (cas 13010-47-4) and in situ evaluation of its interaction with DNA08/28/2019